《柳叶刀神经杂志2025》修正；24: 316 - 30

The Lancet Neurology Pub Date : 2025-07-09 DOI:10.1016/s1474-4422(25)00248-0

{"title":"《柳叶刀神经杂志2025》修正；24: 316 - 30","authors":"","doi":"10.1016/s1474-4422(25)00248-0","DOIUrl":null,"url":null,"abstract":"Bateman RJ, Li Y, McDade EM et al. Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial. Lancet Neurol 2025; 24: 316–30—In the Declaration of interests section of this Article, statements have been corrected for Alireza Atri. A grant number has been corrected, and the appendix has been resupplied. These corrections have been made to the online version as of July 9, 2025.","PeriodicalId":22676,"journal":{"name":"The Lancet Neurology","volume":"34 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Correction to Lancet Neurol 2025; 24: 316–30\",\"authors\":\"\",\"doi\":\"10.1016/s1474-4422(25)00248-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Bateman RJ, Li Y, McDade EM et al. Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial. Lancet Neurol 2025; 24: 316–30—In the Declaration of interests section of this Article, statements have been corrected for Alireza Atri. A grant number has been corrected, and the appendix has been resupplied. These corrections have been made to the online version as of July 9, 2025.\",\"PeriodicalId\":22676,\"journal\":{\"name\":\"The Lancet Neurology\",\"volume\":\"34 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-07-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Lancet Neurology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/s1474-4422(25)00248-0\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet Neurology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s1474-4422(25)00248-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

贝特曼RJ，李勇，McDade EM等。gantenerumab长期治疗显性遗传性阿尔茨海默病的安全性和有效性：2/3期多中心、随机、双盲、安慰剂对照平台DIAN-TU试验的开放标签扩展柳叶刀神经杂志2025；[04:316 - 30]在本文的利益申报部分，对Alireza Atri的陈述进行了更正。拨款编号已更正，附录已重新提供。这些更正已于2025年7月9日对在线版本进行了修改。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Correction to Lancet Neurol 2025; 24: 316–30

Bateman RJ, Li Y, McDade EM et al. Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial. Lancet Neurol 2025; 24: 316–30—In the Declaration of interests section of this Article, statements have been corrected for Alireza Atri. A grant number has been corrected, and the appendix has been resupplied. These corrections have been made to the online version as of July 9, 2025.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

The Lancet Neurology

自引率

0.00%

发文量